The lawyers involved in the first West Coast trial against the maker of Vioxx are butting heads over whether jurors should decide one or more of the cases at the same time.

More than 1,800 lawsuits have been filed in California against Merck & Co. Inc. alleging that executives promoted the prescription pain reliever even though they knew it might cause patients to die or suffer from heart attacks.

The suits are among more than 9,600 filed nationwide by alleged victims and their families since September 2004, when Merck removed Vioxx from the market.

The first trial in California is set for June 21. Recently, Los Angeles Superior Court Judge Victoria Chaney narrowed a list of 36 potential first cases by eliminating all but victims of myocardial infarction, an ailment similar to a heart attack.

But she left open the possibility that more than one case could go to trial-a critical issue for lawyers on both sides. In re Vioxx Coordinated Cases, No. JCCP 4247 (Los Angeles Co., Calif., Super. Ct.).

“I want to know more about the cases we’re going to try, their similarities and dissimilarities,” she told a packed courtroom of about 25 lawyers. “I need to know if it’s best to do single or multiple.”

MANAGING VIOXX CASES

So far, three cases against Merck have ended in verdicts, and Merck, based in Whitehouse Station, N.J., has won two of them. The company faces trial this month in Atlantic City, N.J., and Rio Grande City, Texas.

In Los Angeles, steering committees made up mostly of West Coast lawyers have spent the past year consolidating the cases filed in California.

As of last week, a total of 1,882 cases had been filed, more than half by California residents, according to lawyers’ reports.

Ten law firms are representing Merck in California, where about 75 law firms have brought cases.

Plaintiffs lawyers urged the judge to pick more than one case for the upcoming trial. Mark Robinson Jr., senior partner at Robinson, Calcagnie & Robinson in Newport Beach, Calif., and a lead member of the plaintiffs’ steering committee who spoke at the hearing, said that 80% of the Vioxx cases rely on the same experts. The facts of the cases are generally the same, he said.

Ralph Campillo, a partner in the Los Angeles office of San Francisco-based Sedgwick, Detert, Moran & Arnold, who is the lead defense attorney representing Merck in California, said that the cases should be tried individually.

He said that specific facts of the case—such as the plaintiff’s medical history, the physician’s knowledge of the harmful effects of Vioxx and the time frame in which each patient took the drug—could confuse the jury.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Merck to pay $830 million to settle investors’ Vioxx...

Merck announced Friday it will pay $830 million to settle investor complaints accusing it of committing...

Merck to pay nearly $1 billion for illegal marketing...

American pharmaceutical company Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal...

Merck paying more than 3,100 vioxx death claims

Merck & Co. is paying claims by the families of more than 3,100 users of its Vioxx painkiller who...

Settlement limits insurers' claims in Vioxx deal

TRENTON, N.J. (AP) -- Former Vioxx users getting part of a $4.85 billion settlement ending most personal...

Persistence pays in Vioxx litigation

Plaintiffs get close to $5B, but Merck could have done a lot worse. Attorneys who spent nearly one year...

Vioxx settlement payments to begin in August

Merck & Co., manufacturer of Vioxx, announced it will make the first payment of $500 million on Aug....

Highly recommended

I would highly recommend this law firm to handle any of your legal needs.

—Sandy